Abivax SA American Depositary Shares (ABVX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Abivax SA American Depositary Shares (ABVX) has a cash flow conversion efficiency ratio of -0.051x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.23 Million) by net assets ($455.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Abivax SA American Depositary Shares - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Abivax SA American Depositary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Abivax SA American Depositary Shares for a breakdown of total debt and financial obligations.
Abivax SA American Depositary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abivax SA American Depositary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mineral Resources Ltd
AU:MIN
|
0.209x |
|
Masimo Corporation
NASDAQ:MASI
|
0.084x |
|
Sunoco LP
NYSE:SUN
|
0.072x |
|
MGM Resorts International
NYSE:MGM
|
0.200x |
|
Enlight Renewable Energy Ltd
TA:ENLT
|
0.011x |
|
Chart Industries Inc
NYSE:GTLS
|
0.035x |
|
Jefferies Financial Group Inc
NYSE:JEF
|
-0.163x |
|
CAVA Group, Inc.
NYSE:CAVA
|
0.052x |
Annual Cash Flow Conversion Efficiency for Abivax SA American Depositary Shares (2014–2025)
The table below shows the annual cash flow conversion efficiency of Abivax SA American Depositary Shares from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Abivax SA American Depositary Shares (ABVX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $455.01 Million | $-155.69 Million | -0.342x | +90.99% |
| 2024-12-31 | $40.58 Million | $-154.07 Million | -3.796x | -644.06% |
| 2023-12-31 | $196.01 Million | $-100.01 Million | -0.510x | +93.20% |
| 2022-12-31 | $7.19 Million | $-53.94 Million | -7.503x | -326.14% |
| 2021-12-31 | $25.93 Million | $-45.66 Million | -1.761x | -5.67% |
| 2020-12-31 | $17.90 Million | $-29.82 Million | -1.666x | -12.75% |
| 2019-12-31 | $18.59 Million | $-27.47 Million | -1.478x | -250.67% |
| 2018-12-31 | $34.66 Million | $-14.60 Million | -0.421x | -140.29% |
| 2017-12-31 | $48.18 Million | $-8.45 Million | -0.175x | +36.28% |
| 2016-12-31 | $56.72 Million | $-15.61 Million | -0.275x | -32.51% |
| 2015-12-31 | $71.77 Million | $-14.90 Million | -0.208x | -113.23% |
| 2014-12-31 | $33.94 Million | $-3.31 Million | -0.097x | -- |
About Abivax SA American Depositary Shares
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as … Read more